Lawrence H Yang1, Bruce G Link2, Shelly Ben-David3, Kelly E Gill4, Ragy R Girgis5, Gary Brucato6, Ahtoy J Wonpat-Borja7, Cheryl M Corcoran8. 1. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: lhy2001@cumc.columbia.edu. 2. University of California Riverside, 900 University Avenue, Riverside, CA 92521, USA. Electronic address: bruce.link@ucr.edu. 3. New York University Silver School of Social Work, 1 Washington Square North, New York, NY 10003, USA. Electronic address: sbd268@nyu.edu. 4. The Catholic University of America, 620 Michigan Ave. NE, Washington, DC 20064, USA. Electronic address: kegill13@gmail.com. 5. New York State Psychiatric Institute at Columbia University, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: ragygir@nyspi.columbia.edu. 6. New York State Psychiatric Institute at Columbia University, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: gb2428@cumc.columbia.edu. 7. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: aw258@columbia.edu. 8. New York State Psychiatric Institute at Columbia University, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: Corcora@nyspi.columbia.edu.
Abstract
BACKGROUND: Despite advances that the psychosis "clinical high-risk" (CHR) identification offers, risk of stigma exists. Awareness of and agreement with stereotypes has not yet been evaluated in CHR individuals. Furthermore, the relative stigma associated with symptoms, as opposed to the label of risk, is not known, which is critical because CHR identification may reduce symptom-related stigma. METHODS: Thirty-eight CHR subjects were ascertained using standard measures from the Center of Prevention and Evaluation/New York State Psychiatric Institute/ Columbia University. Labeling-related measures adapted to the CHR group included "stereotype awareness and self-stigma" ("Stereotype awareness", "Stereotype Agreement", "Negative emotions [shame]"), and a parallel measure of "Negative emotions (shame)" for symptoms. These measures were examined in relation to symptoms of anxiety and depression, adjusting for core CHR symptoms (e.g. attenuated psychotic symptoms). RESULTS: CHR participants endorsed awareness of mental illness stereotypes, but largely did not themselves agree with these stereotypes. Furthermore, CHR participants described more stigma associated with symptoms than they did with the risk-label itself. Shame related to symptoms was associated with depression, while shame related to the risk-label was associated with anxiety. CONCLUSION: Both stigma of the risk-label and of symptoms contribute to the experience of CHR individuals. Stereotype awareness was relatively high and labeling-related shame was associated with increased anxiety. Yet limited agreement with stereotypes indicated that labeling-related stigma had not fully permeated self-conceptions. Furthermore, symptom-related stigma appeared more salient overall and was linked with increased depression, suggesting that alleviating symptom-related shame via treating symptoms might provide major benefit.
BACKGROUND: Despite advances that the psychosis "clinical high-risk" (CHR) identification offers, risk of stigma exists. Awareness of and agreement with stereotypes has not yet been evaluated in CHR individuals. Furthermore, the relative stigma associated with symptoms, as opposed to the label of risk, is not known, which is critical because CHR identification may reduce symptom-related stigma. METHODS: Thirty-eight CHR subjects were ascertained using standard measures from the Center of Prevention and Evaluation/New York State Psychiatric Institute/ Columbia University. Labeling-related measures adapted to the CHR group included "stereotype awareness and self-stigma" ("Stereotype awareness", "Stereotype Agreement", "Negative emotions [shame]"), and a parallel measure of "Negative emotions (shame)" for symptoms. These measures were examined in relation to symptoms of anxiety and depression, adjusting for core CHR symptoms (e.g. attenuated psychotic symptoms). RESULTS: CHR participants endorsed awareness of mental illness stereotypes, but largely did not themselves agree with these stereotypes. Furthermore, CHR participants described more stigma associated with symptoms than they did with the risk-label itself. Shame related to symptoms was associated with depression, while shame related to the risk-label was associated with anxiety. CONCLUSION: Both stigma of the risk-label and of symptoms contribute to the experience of CHR individuals. Stereotype awareness was relatively high and labeling-related shame was associated with increased anxiety. Yet limited agreement with stereotypes indicated that labeling-related stigma had not fully permeated self-conceptions. Furthermore, symptom-related stigma appeared more salient overall and was linked with increased depression, suggesting that alleviating symptom-related shame via treating symptoms might provide major benefit.
Authors: K A Hawkins; T H McGlashan; D Quinlan; T J Miller; D O Perkins; R B Zipursky; J Addington; S W Woods Journal: Schizophr Res Date: 2004-06-01 Impact factor: 4.939
Authors: Tandy J Miller; Thomas H McGlashan; Joanna L Rosen; Kristen Cadenhead; Tyrone Cannon; Joseph Ventura; William McFarlane; Diana O Perkins; Godfrey D Pearlson; Scott W Woods Journal: Schizophr Bull Date: 2003 Impact factor: 9.306
Authors: G Brucato; M D Masucci; L Y Arndt; S Ben-David; T Colibazzi; C M Corcoran; A H Crumbley; F M Crump; K E Gill; D Kimhy; A Lister; S A Schobel; L H Yang; J A Lieberman; R R Girgis Journal: Psychol Med Date: 2017-03-02 Impact factor: 7.723
Authors: Lawrence H Yang; Kristen A Woodberry; Bruce G Link; Cheryl M Corcoran; Caitlin Bryant; Daniel I Shapiro; Donna Downing; Ragy R Girgis; Gary Brucato; Debbie Huang; Francesca M Crump; Mary Verdi; William R McFarlane; Larry J Seidman Journal: Schizophr Res Date: 2019-02-19 Impact factor: 4.939
Authors: Joseph S DeLuca; Lawrence H Yang; Alicia A Lucksted; Philip T Yanos; Jordan DeVylder; Deidre M Anglin; Yulia Landa; Cheryl M Corcoran Journal: Schizophr Bull Date: 2021-10-21 Impact factor: 7.348
Authors: Emmett M Larsen; Shaynna Herrera; Zarina R Bilgrami; Riaz B Shaik; Francesca Crump; Cansu Sarac; Jenny Shen; Lawrence H Yang; Cheryl M Corcoran Journal: Schizophr Res Date: 2019-01-28 Impact factor: 4.939
Authors: Jordan E DeVylder; Danielle R Jahn; Tracie Doherty; Camille S Wilson; Holly C Wilcox; Jason Schiffman; Matthew R Hilimire Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2015-10-22 Impact factor: 4.328
Authors: Cansu Sarac; Joseph S DeLuca; Zarina R Bilgrami; Shaynna N Herrera; Jonathan J Myers; Matthew F Dobbs; Shalaila S Haas; Therese L Todd; Agrima Srivastava; Rachel Jespersen; Riaz B Shaik; Yulia Landa; Larry Davidson; Anthony J Pavlo; Cheryl M Corcoran Journal: Psychiatr Rehabil J Date: 2021-06-17